Immunosuppression for ipilimumab-related toxicity can cause pneumocystis pneumonia but spare antitumor immune control
Ipilimumab is a standard therapy for advanced melanoma. Severe immune related adverse events occur in up to 30% of patients and require treatment with immunosuppressants such as steroids or the anti-TNFα antibody, infliximab. We describe two patients with advanced melanoma treated with ipilimumab. B...
Saved in:
| Published in: | Oncoimmunology Vol. 4; no. 10; p. e1040218 |
|---|---|
| Main Authors: | , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
Taylor & Francis
03-10-2015
|
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Ipilimumab is a standard therapy for advanced melanoma. Severe immune related adverse events occur in up to 30% of patients and require treatment with immunosuppressants such as steroids or the anti-TNFα antibody, infliximab. We describe two patients with advanced melanoma treated with ipilimumab. Both suffered from severe immune related side effects and required prolonged immunosuppression with steroids and/or infliximab. Both patients recovered and in spite of the immune suppression, demonstrate clinical evidence of tumor control. This argues that distinct immunological effector functions control nosocomial infection and tumor, respectively. To our knowledge, these are also the first two case reports of pneumocystis pneumonia in this setting. |
|---|---|
| AbstractList | Ipilimumab is a standard therapy for advanced melanoma. Severe immune related adverse events occur in up to 30% of patients and require treatment with immunosuppressants such as steroids or the anti-TNFα antibody, infliximab. We describe two patients with advanced melanoma treated with ipilimumab. Both suffered from severe immune related side effects and required prolonged immunosuppression with steroids and/or infliximab. Both patients recovered and in spite of the immune suppression, demonstrate clinical evidence of tumor control. This argues that distinct immunological effector functions control nosocomial infection and tumor, respectively. To our knowledge, these are also the first two case reports of pneumocystis pneumonia in this setting. |
| Author | Foria, Vipul Krishnan, Radhika Smart, James Ottensmeier, Christian Wheater, Matthew Arriola, Edurne |
| Author_xml | – sequence: 1 givenname: Edurne surname: Arriola fullname: Arriola, Edurne organization: Cancer Sciences Unit; University of Southampton and University Hospital Southampton NHS Foundation Trust ; Southampton, UK ; University Hospital Southampton NHS Foundation Trust ; Southampton, UK ; Southampton Experimental Cancer Medicine Center; University of Southampton and University Hospital Southampton NHS Foundation Trust ; Southampton, UK – sequence: 2 givenname: Matthew surname: Wheater fullname: Wheater, Matthew organization: University Hospital Southampton NHS Foundation Trust ; Southampton, UK ; Southampton Experimental Cancer Medicine Center; University of Southampton and University Hospital Southampton NHS Foundation Trust ; Southampton, UK – sequence: 3 givenname: Radhika surname: Krishnan fullname: Krishnan, Radhika organization: University Hospital Southampton NHS Foundation Trust ; Southampton, UK – sequence: 4 givenname: James surname: Smart fullname: Smart, James organization: University Hospital Southampton NHS Foundation Trust ; Southampton, UK – sequence: 5 givenname: Vipul surname: Foria fullname: Foria, Vipul organization: University Hospital Southampton NHS Foundation Trust ; Southampton, UK – sequence: 6 givenname: Christian surname: Ottensmeier fullname: Ottensmeier, Christian organization: Cancer Sciences Unit; University of Southampton and University Hospital Southampton NHS Foundation Trust ; Southampton, UK ; University Hospital Southampton NHS Foundation Trust ; Southampton, UK ; Southampton Experimental Cancer Medicine Center; University of Southampton and University Hospital Southampton NHS Foundation Trust ; Southampton, UK |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/26451305$$D View this record in MEDLINE/PubMed |
| BookMark | eNpVUU1r3DAQFWVDk2zyE1J07MXpSLZl-RIIIU0CC70ksDchy3KrYEuuPkr231cmztIOiJl5M_Oe4J2jjXVWI3RF4JoAh2-UMFoBfbumQOoM5ZrwT-hswYvc7DfHmpBTdBnCK-RgULOy_YxOKatqUkJ9htLTNCXrQppnr0MwzuLBeWxmM5opTbIrvB5l1D2O7s0oEw9YSZtfChrPVqfJqUOIJqyNNRJ3KeIwS6-xtNHEjGbCRUZj5Wz0brxAJ4Mcg75c8xa9fL9_vnssdj8enu5ud4WqmiYWFeWSDlA2bQ2EK-h5r2jDoaF9pRrSs3boO1pXlEqqiF6QjkFLu4HxJg_LLbp5551TN-le6awuRzF7M0l_EE4a8f_Eml_ip_sjqpq3wMpM8HUl8O530iGKyQSlx1Fa7VIQhFPGSiAU8mr9vqq8C8Hr4ShDQCyuidW1vVhcE6tr-e7Lv388Xn14VP4FNSSYXQ |
| CitedBy_id | crossref_primary_10_1080_14740338_2017_1313228 crossref_primary_10_1200_EDBK_209557 crossref_primary_10_1007_s12032_020_01357_x crossref_primary_10_36290_far_2019_019 crossref_primary_10_1186_s12882_016_0408_2 crossref_primary_10_1007_s40588_020_00154_4 crossref_primary_10_1016_j_jpainsymman_2023_02_316 crossref_primary_10_1007_s40278_015_5700_6 crossref_primary_10_1007_s00262_017_1962_6 crossref_primary_10_1097_CCM_0000000000004087 crossref_primary_10_1093_cid_ciaa802 crossref_primary_10_1136_thoraxjnl_2021_217260 crossref_primary_10_1371_journal_ppat_1011845 crossref_primary_10_1016_j_critrevonc_2017_10_009 crossref_primary_10_1177_1535370220939862 crossref_primary_10_1007_s00520_020_05708_2 crossref_primary_10_1016_j_cmi_2018_01_030 crossref_primary_10_1093_cid_ciw539 crossref_primary_10_1158_1078_0432_CCR_15_2569 crossref_primary_10_1111_myc_12621 crossref_primary_10_1016_j_tranon_2023_101787 crossref_primary_10_1016_j_clml_2021_10_012 crossref_primary_10_1093_mmy_myy165 crossref_primary_10_1097_MCC_0000000000000978 crossref_primary_10_1136_jitc_2020_000577 crossref_primary_10_1016_j_jinf_2019_10_022 crossref_primary_10_3390_cancers15071989 crossref_primary_10_3389_fphar_2023_1129730 crossref_primary_10_1186_s12890_021_01649_6 crossref_primary_10_3390_jof7080625 crossref_primary_10_3390_cells10092227 crossref_primary_10_1056_NEJMra1703481 crossref_primary_10_1073_pnas_1611421113 crossref_primary_10_4103_JIPO_JIPO_23_19 crossref_primary_10_1097_MCP_0000000000000382 crossref_primary_10_2169_internalmedicine_1163_22 |
| Cites_doi | 10.1038/nature13904 10.3201/eid1903.121151 10.1158/1078-0432.CCR-07-0187 10.1056/NEJMoa1003466 10.1007/s10620-009-0839-8 10.1016/j.autrev.2010.11.009 10.1634/theoncologist.2012-0483 10.1007/s00281-014-0459-z 10.1016/j.clim.2007.08.013 10.1172/JCI119384 10.3201/eid1010.030985 10.1126/scitranslmed.3008918 10.14694/EdBook_AM.2012.32.174 10.4049/jimmunol.176.10.6147 10.1186/2051-1426-2-19 |
| ContentType | Journal Article |
| Copyright | 2015 Taylor & Francis Group, LLC 2015 Taylor & Francis Group, LLC |
| Copyright_xml | – notice: 2015 Taylor & Francis Group, LLC 2015 Taylor & Francis Group, LLC |
| DBID | NPM AAYXX CITATION 7X8 5PM |
| DOI | 10.1080/2162402x.2015.1040218 |
| DatabaseName | PubMed CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | PubMed CrossRef MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 2162-402X |
| EndPage | e1040218 |
| ExternalDocumentID | 10_1080_2162402X_2015_1040218 26451305 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: Cancer Research UK grantid: 12135 – fundername: Cancer Research UK grantid: 15951 |
| GroupedDBID | 00X 0YH 4.4 53G AAKDD ABDBF ABUPF ACENM ACGFS ADBBV ADCVX AENEX AIJEM ALMA_UNASSIGNED_HOLDINGS AOIJS BABNJ BLEHA CCCUG DEAQA DGEBU DGFLZ EBD EBS EJD EUPTU GROUPED_DOAJ H13 HYE KRBQP KSSTO KTTOD KWAYT KYCEM LJTGL M4Z NPM O9- OK1 OVD RPM TDBHL TEORI TFL TFW TNTFI TTHFI AAYXX CITATION 7X8 5PM |
| ID | FETCH-LOGICAL-c477t-428a2f03795018c0d8dc278072d4c71d69fdb25422a2c1e71d6b6092bf68769f3 |
| IEDL.DBID | RPM |
| ISSN | 2162-4011 2162-402X |
| IngestDate | Tue Sep 17 21:29:10 EDT 2024 Fri Oct 25 02:12:38 EDT 2024 Fri Aug 23 02:42:27 EDT 2024 Sat Nov 02 12:23:38 EDT 2024 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 10 |
| Keywords | pneumocystis pneumonia opportunistic infliximab ipilimumab immunosuppression melanoma steroids |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c477t-428a2f03795018c0d8dc278072d4c71d69fdb25422a2c1e71d6b6092bf68769f3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0001-6561-5290 |
| OpenAccessLink | https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2015.1040218?needAccess=true |
| PMID | 26451305 |
| PQID | 1826630120 |
| PQPubID | 23479 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_4589063 proquest_miscellaneous_1826630120 crossref_primary_10_1080_2162402X_2015_1040218 pubmed_primary_26451305 |
| PublicationCentury | 2000 |
| PublicationDate | 2015-10-03 |
| PublicationDateYYYYMMDD | 2015-10-03 |
| PublicationDate_xml | – month: 10 year: 2015 text: 2015-10-03 day: 03 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Oncoimmunology |
| PublicationTitleAlternate | Oncoimmunology |
| PublicationYear | 2015 |
| Publisher | Taylor & Francis |
| Publisher_xml | – name: Taylor & Francis |
| References | CIT0010 CIT0001 CIT0012 CIT0011 CIT0003 CIT0014 CIT0002 CIT0013 CIT0005 CIT0004 CIT0015 CIT0007 CIT0006 CIT0009 CIT0008 |
| References_xml | – ident: CIT0002 doi: 10.1038/nature13904 – ident: CIT0009 doi: 10.3201/eid1903.121151 – ident: CIT0005 doi: 10.1158/1078-0432.CCR-07-0187 – ident: CIT0001 doi: 10.1056/NEJMoa1003466 – ident: CIT0006 doi: 10.1007/s10620-009-0839-8 – ident: CIT0010 doi: 10.1016/j.autrev.2010.11.009 – ident: CIT0004 doi: 10.1634/theoncologist.2012-0483 – ident: CIT0012 doi: 10.1007/s00281-014-0459-z – ident: CIT0011 doi: 10.1016/j.clim.2007.08.013 – ident: CIT0014 doi: 10.1172/JCI119384 – ident: CIT0008 doi: 10.3201/eid1010.030985 – ident: CIT0015 doi: 10.1126/scitranslmed.3008918 – ident: CIT0003 doi: 10.14694/EdBook_AM.2012.32.174 – ident: CIT0013 doi: 10.4049/jimmunol.176.10.6147 – ident: CIT0007 doi: 10.1186/2051-1426-2-19 |
| SSID | ssj0000605639 |
| Score | 2.2820034 |
| Snippet | Ipilimumab is a standard therapy for advanced melanoma. Severe immune related adverse events occur in up to 30% of patients and require treatment with... |
| SourceID | pubmedcentral proquest crossref pubmed |
| SourceType | Open Access Repository Aggregation Database Index Database |
| StartPage | e1040218 |
| SubjectTerms | Brief Report |
| Title | Immunosuppression for ipilimumab-related toxicity can cause pneumocystis pneumonia but spare antitumor immune control |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/26451305 https://search.proquest.com/docview/1826630120 https://pubmed.ncbi.nlm.nih.gov/PMC4589063 |
| Volume | 4 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Li9RAEC6cBcGL-HZ80YLXzCTdeR5l3WU9KIIKewv9qGBg0wmbaXD_vVV5LDt685BDd5JOUlXpqqK_rxrgg0NUsildRM5ARWlOMZxWDTdTh1klUU2J4sX34utl-emMy-RkKxdmAu1b0-78Vbfz7a8JWzl0dr_ixPbfvpymWVmRa91vYEOx4Z0UfZ5-yadPO4jJhBlBZMArc6eM99xHKdMlg7oyXuBkH8cVgfM0o-k8O3ZP_8Scf0Mn7_ii80fwcAkixcf5ZR_DPfRP4P68reTNUwifmfTRj2FYUK5eUGgq2qG9arvQaRNNDBZ04tD_bi3F4YIETEcYUQweQ9fbG_r1x6XhWy1MOIiR0epCM7GXemlAfgyKBe3-DH6en_04vYiW7RUimxbFIaLEQ8smVkXFRf1s7EpnZVHGhXSpLRKXV40zlD9KqaVNkHtMHlfSNDlNoVWjnsOJ7z2-BJErZfIyTh2NkWrUxipyvrEqjUKUmGxht0q1HuYqGnWyFCddNVKzRupFI1t4v8q-JnvnRQztsQ9jzflQrpjyu4UXsy5uh1yVuIXiSEu3F3At7eMzZGJTTe3FpF79952v4QF_wITzU2_g5HAd8C1sRhfeTfb5B0Z46oA |
| link.rule.ids | 230,315,729,782,786,887,27934,27935,53802,53804 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Jb9UwEB7RIgQXKPuDFozENe8ldtYj6qJX0VZIFKm3yFvUSI0TkWeJ_ntmslR9cOshB9uJI-uzZ5G_mQH4aqwVvMpNgMpABHGKNpwUFTVjY5OCWzE4iuuf2cVVfnRMaXKSORZmIO1rVS_dTbN09fXArewavZp5Yqsf54dxkheoWlc78BjPa8jvOemjAEatPtQQ4xHFBOEWnmN38nBFfeg0XRGtK6ErTtJylBM4jRMU6Mm2gvrP6vyXPHlPG528eOA69uD5ZH6yb-PwS3hk3St4MhakvH0N_pTCRdredxM_1jE0alnd1Td14xupgiH2xRq2af_UGi14htDg43vLOmd90-pbFBr91HC1ZMpvWE88dyYpJBh7cUL6jWUTT_4N_Do5vjxcB1NhhkDHWbYJ0GWRvApFVlA6QB2a3Gie5WHGTayzyKRFZRR6npxLriNLPSoNC66qFIVvUYm3sOtaZ98DS4VQaR7GBueIpZVKC1TbociVsJbbaAHLGY2yG_NvlNGU1nRGsiQkywnJBXyZMSvxpND1h3S29X1JnlQqKFh4Ae9GDO-mnMFfQLaF7t0LlIV7ewRBHbJxTyB-ePCXn-Hp-vL8rDw7vfj-EZ7RYga2oNiH3c1vbw9gpzf-07DH_wKi3wAc |
| linkToPdf | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Jb9UwEB7RIhAX9uWxGolrXhI76xG1fWoFVJUAqbfIW0SkxonIs0T_PTNZnvrgBocc7DiOrM-eRf5mBuCDsVbwujABKgMRJBnacFLU1EyMTUtuxegonn7Nzy-L4xNKk7Mr9TWS9rVq1u6qXbvmx8it7FsdLjyx8OLLUZIWJarWsDd1eAC38cxGyQ1HfRLCqNnHOmI8prgg3MZL_E4RhdSHjtMlUbtSuuYkTUd5gbMkRaGe7iupvyzPPwmUNzTS5sF_rOUh3J_NUPZxGvIIbln3GO5MhSmvn4A_o7CRbvD9zJN1DI1b1vTNVdP6VqpgjIGxhm27X41GS54hRPj4wbLeWd92-hqFxzA3XCOZ8ls2EN-dSQoNxl6ckH5j2cyXfwrfNyffjk6DuUBDoJM83wboukheRyIvKS2gjkxhNM-LKOcm0XlssrI2Cj1QziXXsaUelUUlV3WGQrisxTM4dJ2zL4BlQqgMYTQ4RyKtVFqg-o5EoYS13MYrWC-IVP2Uh6OK5_SmC5oVoVnNaK7g_YJbhSeGrkGks50fKvKoMkFBwyt4PuG4m3LZACvI9xDeDaBs3PtvENgxK_cM5Mt__vId3L043lSfz84_vYJ7tJaRNChew-H2p7dv4GAw_u24zX8DsBMCnA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Immunosuppression+for+ipilimumab-related+toxicity+can+cause+pneumocystis+pneumonia+but+spare+antitumor+immune+control&rft.jtitle=Oncoimmunology&rft.au=Arriola%2C+Edurne&rft.au=Wheater%2C+Matthew&rft.au=Krishnan%2C+Radhika&rft.au=Smart%2C+James&rft.date=2015-10-03&rft.issn=2162-4011&rft.volume=4&rft.issue=10&rft.spage=e1040218&rft.epage=e1040218&rft_id=info:doi/10.1080%2F2162402x.2015.1040218&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2162-4011&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2162-4011&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2162-4011&client=summon |